Disease Landscape and Forecast Insights

A comprehensive, quantitative understanding of patient progression through all stages of disease management and treatment is critical in both assessing a market opportunity within a therapeutic…

The multiple myeloma therapy market has witnessed considerable advances in recent years. Effective therapies such as Thalomid, Revlimid, Velcade, Pomalyst, and Kyprolis have transformed the…

Gastroesophageal reflux disease (GERD) is arguably the most common chronic gastrointestinal disorder, characterized by symptoms of heartburn and regurgitation. The primary objectives of GERD…

Growth hormone is an endogenous hormone produced by the pituitary gland; a deficiency in its production or activity is characterized by short stature, decreased capacity for exercise, and…

This analysis focuses on the posthospital, secondary prevention of acute coronary syndrome (ACS), which typically involves the implementation of antithrombotic, neurohormonal blocking, and lipid-…

The premium-priced therapies used to treat ovarian cancer, such as Avastin (Roche/Genentech) and the PARP inhibitors Lynparza (AstraZeneca/Merck & Co), Rubraca (Clovis Oncology), and Zejula (…

Rheumatoid arthritis (RA) is disease characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue damage and cartilage and bone destruction…

Market OutlookClinical pathways, which establish optimal treatment protocols for specific patient populations based on the best evidence, have become increasingly prevalent in the treatment of…

MARKET OUTLOOK Progress in R&D and technology, regulatory and monetary incentives for advancing the development of treatments for rare diseases, and ongoing focus by the pharmaceutical market…

Childhood absence epilepsy (CAE) is characterized by frequent and brief absence seizures in children aged 4-12 and is diagnosed in approximately 10-15% of all childhood epilepsies. Only a handful…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stemcell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML). Although…

MARKET OUTLOOK Tumor necrosis factor-alpha (TNF-α) inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia) are approved for the treatment of…